

+ Evidence in focus

Arthroplasty registry analysis: UK NJR bespoke report LEGION Revision OXINIUM (with revision tibia)

Smith+Nephew

LEGION[◇] Revision OXINIUM[◇] total knee arthroplasty (rTKA) demonstrates favourable long-term survivorship at 12 years

+ Plus points



LEGION Revision OXINIUM survivorship is numerically higher than the class average for rTKAs



Significantly fewer re-revisions due to aseptic loosening of the femur (p=0.025) and periprosthetic fracture (p=0.045) compared to the class average for rTKAs



Comparable levels of patient satisfaction to the class average for rTKAs

Overview

- Bespoke implant report produced by the NJR summarising usage and outcomes associated with LEGION Revision OXINIUM (with revision tibial)
- The analysis is based on data collected by the NJR and patient-reported outcome measures (PROMs) data collected by NHS: UK National Health Service Digital†
- LEGION Revision OXINIUM usage between April 2006 and June 2020
 - 2,555 rTKAs
 - 2,502 patients
 - 313 implanting surgeons at 131 centres

Results

- Registry data shows that LEGION Revision OXINIUM demonstrates:
 - A numerically lower re-revision rate compared to the class average for rTKAs in NJR at 12 years (10.8 vs 12.5%; Figure)
 - Significantly fewer re-revisions due to aseptic loosening of the femur compared to the class average for rTKAs in NJR (p=0.025)
 - Significantly fewer re-revisions due to periprosthetic fracture compared to the class average for rTKAs in NJR (p=0.045)
 - Similar patient-reported outcome scores and levels of patient satisfaction compared to the class average for rTKAs in NJR




Figure. Cumulative re-revision rate of LEGION Revision OXINIUM compared to the class average for rTKAs in NJR, with endpoint of any reason for re-revision

Conclusion

LEGION Revision OXINIUM demonstrates a favourable 12-year survivorship, comparable to all other rTKAs in NJR.

Citation

*National Joint Registry for England, Wales and Northern Ireland: LEGION revision OXINIUM (with revision tibial) implant summary report. 25 August 2020.
Available at: <https://bit.ly/3lOCC56>

†The data used for this analysis was obtained from the NJR Supplier Feedback System. The Healthcare Quality Improvement Partnership ("HQIP") and/or the National Joint Registry ("NJR") take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.